Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Demographic and geographic hotspots due to lymphoma-related mortality: A 21-year retrospective analysis.

Shafiq Ur Rahman, Iqra Shahid, Hassan Ijaz et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19079

e19079 Background: About half of the blood cancers that occur each year are lymphomas, or cancers of the lymphatic system. This system - composed of lymph...

Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Updated safety and efficacy of a phase 1b/2 study (RAMP 205).

Kian-Huat Lim, Rachael A Safyan, Kimberly Perez et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16403

e16403 Background: Activating KRAS mutations in pancreatic ductal carcinomas (PDAC) occur in > 90% of patients (pts). Avutometinib (A) is a RAF/MEK cla...

Efficacy of CAR-T cell therapy versus allogeneic stem cell transplantation in relapsed/refractory B-acute lymphoblastic leukemia: A systematic review of 12 clinical trials.

Pranay Shettywarangale, Saif Syed, Aasim Akthar Ahmed et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18533

e18533 Background: Relapsed/Refractory B- Acute Lymphoblastic Leukemia poses a significant challenge in treatment and is often associated with poorer prog...

Hematological malignancies in the United States: What do mortality trends reveal?

Mishaal Munir, Asfand Yar Cheema, Mian Zahid Jan Kakakhel et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19030

e19030 Background: Hematological malignancies rank as the fifth most commonly diagnosed cancer globally and include leukemia, lymphoma, and myeloma. Their...

Safety and efficacy of neoadjuvant disitamab vedotin in combination with pertuzumab with or without toripalimab for HER2-positive breast cancer: An open-label phase II trial.

Lin-Xiaoxi Ma, Benlong Yang, Shanshan Gu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12596

e12596 Background: Patients with early-stage HER2-positive breast cancer need more effective neoadjuvant treatment choices. Disitamab vedotin is a novel h...

Clinical and molecular insights into pediatric acute myeloid leukemia in resource-constrained settings.

Nathália Meneses Neves, Thamires M.J. Mutran, Renato de Paula Guedes de Oliveira et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22004

e22004 Background: Pediatric Acute Myeloid Leukemia (AML) is a rare and heterogeneous malignancy with variable outcomes across different regions. This stu...

An assessment of end of life care among patients with gastrointestinal cancers who died inpatient at an academic hospital.

Fanny Fanrong Chen, Daniel Jacob Becker Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e24030

e24030 Background: Studies suggest that most patients with cancer prefer to die at home. Despite this established preference, many cancer patients die in...

Evaluating the impact of Medicaid expansion on outcomes for patients with gastric cancer in Louisiana.

Donnell White, Conner D. Hartupee, Denise Danos et al. Jun 01, 2025 pp. 11069-11069 10.1200/jco.2025.43.16_suppl.11069

11069 Background: Prior to June 2016, Louisiana's Medicaid program did not extend coverage to adults, regardless of income. With the expansion, up to 138%...

Dipeptidyl peptidase 9 (DPP9) depletion from hepatocytes in mice to retard tumour growth, increase intrahepatic caspase-1 activation, and alter metabolic markers.

Jiali Carrie Huang, Xinlin Tong, Michelle SunWen Xiang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16303

e16303 Background: Dipeptidyl peptidase 9 (DPP9) is one of four enzymes targeted by a novel compound class that includes talabostat and BXCL701, which hav...

Recombinant human adenovirus type 5 (H101) combined with anti-PD-1 monoclonal antibody in the treatment of patients with advanced melanoma with previous immunotherapy failure: A single-site, single-arm, prospective study.

Jing Lin, Zhongqiao Lin, Huishan Zhang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21505

e21505 Background: Patients with melanoma who progress on immunotherapy have limited treatment options, especially for acral and mucosal melanoma.Here, we...

Trial in progress: ENCORE—Multicenter prospective registry of sequential antibody drug conjugates (ADCs) in HER2 negative metastatic breast cancer (MBC) (TBCRC-067).

Laura Ann Huppert, Leif Ellisen, Carey K. Anders et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps1137

TPS1137 Background: Antibody-drug conjugates (ADCs) have demonstrated substantial improvement in progression free survival (PFS) and overall survival (OS)...

Demographic, socioeconomic, and treatment patterns in malignant Brenner tumors: A National Cancer Database analysis.

Jasmeet Khera, Nikhil A. Furtado, Beau Hsia et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17546

e17546 Background: Malignant Brenner tumor (MBT) is a rare and aggressive subtype of ovarian cancer, accounting for less than 1-2% of all ovarian malignan...

Outcomes of patients with gastrointestinal stromal tumors treated with imatinib and sunitinib in Nepal: A 20-year analysis.

Arun Shahi, Alicia Annamalay, Philip Stevenson et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23520

e23520 Background: Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors of the gastrointestinal tract. Targeted therapies, including imatini...

A geographic information system (GIS)-based analysis of county-level economic and social vulnerabilities in FDA-certified mammogram facilities and breast cancer outcomes in Florida.

LaShae D. Rolle, Maurice J. Chery, Sophia George et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13736

e13736 Background: Breast cancer (BC) is a leading cause of cancer-related morbidity and mortality, with outcomes influenced by socioeconomic factors such...

Implementation of a novel interdisciplinary pharmacology curriculum in a hematology/oncology fellowship program.

Rebecca Forman, Tendai Kwaramba, Rebecca Briana Shamilov et al. Jun 01, 2025 pp. 9028-9028 10.1200/jco.2025.43.16_suppl.9028

9028 Background: Thoroughly understanding cancer therapeutics is a critical component of Hematology/Oncology (HO) training, with pharmacology comprising a...

Postoperative cfDNA levels and ctDNA detection rates in patients with stage II colon cancer screened for CIRCULATE (AIO-KRK-0217, ABCSG).

Sebastian Stasik, Christian Thiede, Sarah Albus et al. Jun 01, 2025 pp. 3610-3610 10.1200/jco.2025.43.16_suppl.3610

3610 Background: Postoperative circulating tumor DNA (ctDNA) has emerged as a prognostic biomarker for disease recurrence...

Determinants of overall survival in the South African Breast Cancer and HIV Outcomes cohort.

Maureen Joffe, Wenlong Carl Chen, Ashleigh Craig et al. Jun 01, 2025 pp. 11158-11158 10.1200/jco.2025.43.16_suppl.11158

11158 Background: Sub-Saharan Africa (SSA) has very low breast cancer (BC) survival. South Africa, unlike most SSA countries, is an upper middle-income co...

Efficacy of triplet therapy based on organoid drug sensitivity testing in lung metastatic hormone-sensitive prostate cancer.

Sentai Ding, Kejia Zhu, Andong Guo et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17101

e17101 Background: Metastatic prostate cancer (mPC) is an advanced stage of prostate cancer, and the presence of visceral metastases in prostate cancer of...

Correlation between germline mutations in homologous recombination repair related genes and clinical characteristics in Chinese patients with breast cancer.

Shiyuan Zhang, Suhan Huang, Fei Yao et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12536

e12536 Background: Poly (ADP-ribose) polymerase inhibitors treatment strategies for BRCA germline muta...

Clinicopathological spectrum of cutaneous carcinoma: A single-center retrospective analysis.

Gurunathan Srinivasan, Faiza Fatima, Lamiya Pirzada et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23260

e23260 Background: Skin carcinomas, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), rank among the most prevalent malignancies glo...

Dose expansion data from iintune-1, a phase 1/2 study of the STING agonist dazostinag plus pembrolizumab as first-line (1L), in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (RM-SCCHN).

Jérôme Fayette, Aron Popovtzer, Martin David Forster et al. Jun 01, 2025 pp. 6020-6020 10.1200/jco.2025.43.16_suppl.6020

6020 Background: Checkpoint inhibitors (CPIs) such as pembrolizumab (pembro) can lead to improved outcomes and durable responses in patients (pts) with RM...

Validating a semantic similarity approach for automated data extraction in phase II oncology trials.

Evelyn Herrmann, Lukas Urs Von Rohr, Fizi Kotta Parambil et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13666

e13666 Background: Manual data extraction from phase II oncology publications is error-prone, especially when text is paraphrased. Traditional exact-match...

Prognostic and predictive impact of next-generation sequencing in metastatic pancreatic ductal adenocarcinoma.

Christopher Schumacher, Henry Hoffman, Sebawe Syaj et al. Jun 01, 2025 pp. 4170-4170 10.1200/jco.2025.43.16_suppl.4170

4170 Background: Outcomes in de novo metastatic pancreatic ductal adenocarcinoma (mPDAC) remain dismal, although considerable hete...

Sequential EHR interventions to increase genetic testing for breast and ovarian cancer predisposition across diverse patient populations in gynecology practices at Penn Medicine.

Heather Heather Symecko, Daniel Blumenthal, Leland Boisseau et al. Jun 01, 2025 pp. 10589-10589 10.1200/jco.2025.43.16_suppl.10589

10589 Background: Genetic testing (GT) identifies individuals who may benefit from increased surveillance and risk reduction strategies. GT is under-utili...

Trajectories of multidimensional worry in survivors of early breast cancer (BC).

Antonio Di Meglio, Martina Pagliuca, Stefano Maccarone et al. Jun 01, 2025 pp. 12051-12051 10.1200/jco.2025.43.16_suppl.12051

12051 Background: Worrisome thoughts are common future-oriented behaviors and may affect quality of life (QoL) years removed from BC diagnosis. We aimed t...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page